证券日报网讯 10月10日晚间，美好医疗发布公告称，经与会职工代表认真审议与民主选举，一致同意 选举周道福先生为公司第二届董事会职工代表董事。 （文章来源：证券日报） ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-066 深圳市美好创亿医疗科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事辞任情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于近日收到公 司董事周道福先生的书面辞职报告。因工作安排原因，周道福先生申请辞去公司 非独立董事职务。周道福先生辞任后将继续担任公司副总经理职务，周道福先生 的辞任不会导致公司董事会人数低于法定最低人数，不存在应履行而未履行的公 开承诺，其书面辞职报告自送达公司董事会之日起生效。 二、选举职工代表董事情况 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等相关规定，公司于2025年10 月10日召开了职工代表大会。经与会职工代表认真审议与民主选举，一致同意选 举周道福先生（简历附后）为公司第二届董事会职工代表董事，任期至第二届董 事会届满之日止。 周道福先生原为公司第二届董事会非职工代表董事，变更为第二届董事会职 工代表董事后，公司第 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-065 深圳市美好创亿医疗科技股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现变更或否决议案的情形； 2、本次股东会不涉及变更前次股东会决议； 3、本次股东会采用现场表决与网络投票相结合的方式召开。 一、会议召开和出席情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）2025年第二次 临时股东会（以下简称"本次股东会"）于2025年10月9日（星期四）15:00召开， 公司已于2025年9月16日披露了《关于召开2025年第二次临时股东会的通知》（公 告编号：2025-064），具体内容详见公司在巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。本次股东会采用现场投票和网络投票相结合的方式召开，会 议有关事项具体如下： 1、现场会议召开时间：2025年10月9日（星期四）15:00 2、现场会议召开地点：广东省惠州市大亚湾西区龙山三路318号美好创亿产 业园A栋8楼801会议室 3、网络投 ...

法律意见书 中国 深圳 福田区 益田路6001号太平金融大厦11、12楼 邮政编码：518038 11F/12F., Taiping Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P.R. China 518038 电话(Tel.)：（0755）8826 5288 传真（Fax.）：（0755）8826 5537 网址（Website）：https://www.sundiallawfirm.com 广东信达律师事务所 关于深圳市美好创亿医疗科技股份有限公司 2025 年第二次临时股东会的 法律意见书 信达会字（2025）第 314 号 致：深圳市美好创亿医疗科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受深圳市美好创亿医疗科技股 份有限公司（以下简称"贵公司"）的委托，指派律师参加了贵公司二〇二五年 第二次临时股东会（以下简称"本次临时股东会"），并进行了必要的验证工作。 现根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股 东会规则》（以下简称"《股东会规则》"）以及贵公司《公司章程》的规定， 按照律师业 ...

证券日报网讯美好医疗（301363）9月30日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东户数为14997户。 ...

融资融券数据显示，该股最新（9月29日）两融余额为1.97亿元，其中，融资余额为1.96亿元，本期筹码 集中以来融资余额合计增加2179.70万元，增幅为12.52%。 公司发布的半年报数据显示，上半年公司共实现营业收入7.33亿元，同比增长3.73%，实现净利润1.14 亿元，同比下降32.44%，基本每股收益为0.2000元，加权平均净资产收益率3.23%。（数据宝） 美好医疗9月30日披露，截至9月20日公司股东户数为14997户，较上期（9月10日）减少1294户，环比降 幅为7.94%。这已是该公司股东户数连续第2期下降。 证券时报•数据宝统计，截至发稿，美好医疗最新股价为24.48元，上涨0.78%，本期筹码集中以来股价 累计下跌7.62%。具体到各交易日，6次上涨，8次下跌。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 ...

Summary of Medical Device and Healthcare Services Industry Conference Call Industry Overview - The medical device sector is experiencing improved growth rates, with significant performance expected in Q3 and the second half of the year, suggesting a focus on companies with improving quarter-over-quarter and year-over-year results, as well as those poised for accelerated growth in 2026 [1][2][6] - High-value consumables and equipment performed relatively well in the first half of the year, with upstream medical device companies like Meihao Medical, Yingke Medical, and Haitai Xinguang showing high growth trends in Q3 [1][3][4] Key Trends and Insights - The strategy of expanding overseas is crucial for Chinese medical device companies to unlock a second growth curve, driven by domestic policy pressures and increased competition from local manufacturers [1][5] - The medical device sector is expected to see a significant improvement in Q3, with companies like Union Medical and Mindray anticipated to show performance turning points [4][8] - The high consumables segment is expected to see further improvement in Q3, benefiting from reduced impact from centralized procurement and the launch of new products, with companies like Huatai and Maipu Chunli Medical projected to achieve high growth [9] Investment Opportunities - Companies with high growth potential or rapid profit growth, such as Meihao Medical and those in the brain-computer interface and humanoid robot supply chains, are recommended for long-term holding [6][7] - Low-valuation companies expected to accelerate growth in 2026 include Meihao Medical, MicroPort Medical, and Yiyuan Technology, among others [12] - The IVD sector is facing challenges but is expected to see improvements in domestic growth rates, while overseas markets maintain high growth [10] Performance of Specific Companies - The Hong Kong medical device sector has shown significant innovation, with companies like Silan Tongqiang and MicroPort Medical demonstrating strong recovery in profitability [14] - The consumption medical services sector, led by Aier Eye Hospital, is outperforming serious medical services, with a notable increase in average transaction prices for procedures [16][17] Valuation and Market Position - The overall valuation of the medical services sector is at historically low levels, with the current PE ratio around the 20% percentile of the past five years [18] - Comprehensive hospitals are facing revenue declines due to healthcare payment reforms, with many experiencing over a 10% drop in income in the first half of 2025 [19][20] Recommendations for Future Monitoring - Long-term investment opportunities exist in both the Hong Kong and A-share medical device sectors, particularly in companies with strong innovation capabilities and international expansion potential [15] - Companies like Aier Eye Hospital and Hai Jiaya Medical are recommended for their leadership in their respective segments, while Yiyuan Medical is noted for its rapid overseas growth and strong cash flow [21][22]

Core Insights - The company reported a revenue of 733 million yuan for H1 2025, representing a year-on-year increase of 3.73%, while the net profit attributable to the parent company was 114 million yuan, a decrease of 32.44% year-on-year [1] Business Analysis - The company experienced strong growth in emerging business sectors, with home respiratory device components generating 436 million yuan (down 2.76% year-on-year), cochlear implant components at 60 million yuan (down 7.53% year-on-year), other medical product components at 76 million yuan (up 54.41% year-on-year), and home and consumer electronics components at 107 million yuan (up 35.69% year-on-year). The company plans to increase investment in strategic emerging business areas to establish a solid foundation for long-term sustainable development [2] - The company is diversifying its business layout in multiple segments such as blood glucose management, cardiovascular, and in vitro diagnostics, aiming to create second and third growth curves. In the blood glucose management sector, breakthroughs have been made in disposable injection pens, continuous glucose monitoring (CGM) devices, and insulin patch pumps. A fully automated production project for insulin injection pens customized for international clients has achieved large-scale production, and the core R&D work for the self-designed "Beautiful Pen" has been completed, with client expansion progressing smoothly [2] - In the in vitro diagnostics field, the company has leveraged its strong technical foundation to achieve significant R&D results in microfluidic chips, detection consumables, reagent packaging materials, and precision components for instruments. Some products have been delivered for validation in small batches, and future business development will be driven by existing customer needs [3] Profit Forecast - The company forecasts revenues of 1.829 billion yuan, 2.294 billion yuan, and 2.741 billion yuan for 2025-2027, with year-on-year growth rates of 14.74%, 25.42%, and 19.47% respectively. The net profit attributable to the parent company is expected to be 402 million yuan, 488 million yuan, and 605 million yuan, with year-on-year growth rates of 10.56%, 21.44%, and 23.92%. The price-to-earnings (PE) ratios for 2025-2027 are projected to be 36.08, 29.71, and 23.98, with corresponding price-to-earnings growth (PEG) ratios of 3.42, 1.39, and 1.00 [4]

Group 1 - The A-share market saw a significant decline in brain-computer interface concept stocks, with several companies experiencing drops of over 5% [1] - Notable companies that fell over 5% include Dineike, Xiangyu Medical, Meihao Medical, Chengdu Huamei, and Tom Cat [1] - Other companies such as Yanshan Technology, Zhongke Information, Aipeng Medical, Nanjing Panda, Weisi Medical, Innovation Medical, Robot, Mailande, Beiqingsong, Botuo Biological, and Rongtai Health dropped over 4% [1]

Investment Rating - The investment rating for the company is "Buy" [8][13] Core Views - The company reported a revenue of 733 million yuan for H1 2025, a year-on-year increase of 3.73%, but the net profit attributable to the parent company decreased by 32.44% to 114 million yuan [3][4] - The company is focusing on strategic emerging business areas, with significant growth in new business segments, including a 54.41% increase in other medical product components revenue [4][5] - The company is diversifying its business in blood glucose management, cardiovascular, and in vitro diagnostics, with ongoing breakthroughs in product technology and CDMO services [5] Company Overview - The latest closing price is 25.51 yuan, with a total market capitalization of 14.5 billion yuan and a circulating market capitalization of 4 billion yuan [2] - The company has a total share capital of 569 million shares, with 156 million shares in circulation [2] - The company has a low debt-to-asset ratio of 11.3% and a price-to-earnings ratio of 28.34 [2] Financial Performance - Revenue projections for 2025-2027 are 1.829 billion yuan, 2.294 billion yuan, and 2.741 billion yuan, with year-on-year growth rates of 14.74%, 25.42%, and 19.47% respectively [6][9] - The net profit attributable to the parent company is expected to reach 402 million yuan, 488 million yuan, and 605 million yuan for the same period, with corresponding growth rates of 10.56%, 21.44%, and 23.92% [6][9] - The company’s earnings per share (EPS) is projected to increase from 0.71 yuan in 2025 to 1.06 yuan in 2027 [9][12]